GlassScriptPhysician profile
Richard L Noel
NPI 1225058852
$6,441.94
in general payments reported to CMS, 2019-2025
21 companies · $918 in 2025
The $918 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $644 · 2021: $906 · 2022: $891 · 2023: $890 · 2024: $1,603 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,410.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $881.19 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $579.67 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $579.55 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $572.81 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $547.95 | 2022-2025 | Ingrezza |
| Abbvie INC. | $481.59 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $440.45 | 2019-2024 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $436.87 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $426.90 | 2020-2025 | Invega Sustenna, Invega Trinza, Invega |
| Supernus Pharmaceuticals, INC. | $337.38 | 2023-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $311.14 | 2021-2025 | Caplyta |
| Eisai INC. | $194.40 | 2020-2023 | |
| Ironshore Pharmaceuticals INC. | $170.25 | 2022 | |
| Lundbeck LLC | $165.60 | 2020-2024 | Rexulti, Abilify Asimtufii |
| Corium, LLC | $82.38 | 2021-2025 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $63.85 | 2022-2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $59.24 | 2019-2020 | |
| Adlon Therapeutics L.P. | $35.57 | 2020 | |
| Allergan, INC. | $34.28 | 2020 | |
| Almatica Pharma LLC | $26.49 | 2023 | Loreev Xr |
| Validus Pharmaceuticals LLC | $14.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Noel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.